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HPA-1a/b (PlA1/A2, Zwa/b): the
odyssey of an alloantigen system
R.H.ASTER AND P.J. NEWMAN
The HPA-1a/b (PlA1/A2, Zwa/b) alloantigen system was
one of the first such systems to be identified on a cell
other than the RBC. From the discovery of HPA-1a in
1958 to the present day, studies of this antigen and its
allele, HPA-1b, have led to a remarkable number of
“firsts” in immunobiology. In this review,we shall trace
the history of the HPA-1a/b system and will highlight
selected observations made during the past 48 years
that have contributed not only to the field of platelet
immunology but also to immunohematology and
transfusion medicine in general.
Serologic Characterization of HPA-1a and 1b,
the First Recognized Platelet-Specific
Alloantigen System
It is likely that an HPA-1a-specific alloantibody was
first identified by Zucker and colleagues1 in 1956 or
1957 in studying a patient who developed profound
thrombocytopenia and hemorrhagic symptoms 5 days
after receiving a blood transfusion. The patient’s serum
contained a strong antibody that produced
agglutination (Fig. 1) and induced complement-
dependent lysis of platelets from four normal subjects
but not with the patient’s own platelets obtained after
recovery, about 4 weeks after the acute episode.
Although the antigen recognized by this antibody was
not characterized further, this case was almost certainly
the first example of a syndrome that was later
designated “posttransfusion purpura” (PTP) associated
with an antibody specific for HPA-1a. Shortly
thereafter, van Loghem and colleagues2 identified a
platelet isoagglutinin in serum from a transfused
patient and showed that it was specific for a marker
they designated “Zwa” that was present in about 98
percent of the Dutch population and was inherited as
a dominant trait. Their studies were facilitated by the
fact that van Loghem himself possessed the rare Zwa-
negative phenotype. At about the same time, Shulman
and colleagues3 at the National Institutes of Health in
Bethesda used platelet agglutination and quantitative
complement fixation to characterize two examples of
an alloantibody specific for a high-frequency
alloantigen they called“platelet antigen 1” (PlA1). It was
soon found that PlA1 and Zwa were identical.4 The
expected allele of Zwa (Zwb) was identified by van der
Weerdt et al.5 as the target for an IgM platelet
isoagglutinin found in a transfused patient. When a
unified nomenclature was developed for platelet-
specific alloantigens, Zwa/PlA1 and Zwb/PlA2 were
designated “HPA-1a” and “HPA-1b,” respectively.6
Analysis of the allelic frequencies of this and other
platelet alloantigen systems suggests that the HPA-1a
epitope was present in the primordial allele of platelet
membrane glycoprotein (GP) IIIa (discussed in a later
Fig. 1. The first anti-HPA-1a–specific antibody was detected on the basis
of its ability to cause complement-dependent lysis of normal
platelets. EDTA platelet-rich plasma was reconstituted with 0.1M
MgCl2. Patient serum (above) but not normal serum (below)
produced platelet fragmentation when the mixture was
incubated at 37°C.*
*Reprinted with permission from Zucker et al.1
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section), traveled with early humans out of Africa
during migrations to Northern Europe approximately
40,000 years ago, and finally came to North America
with European colonists about 500 years ago (Fig. 2).
Today, the approximate gene frequencies of HPA-1a and
HPA-1b in the latter two populations are 0.86 and 0.14,
respectively. However,HPA-1b is much less common in
Amerindians7 and African Americans8 and is extremely
rare in Asians.8,9
Early Studies Led to Identification of Two
Thrombocytopenic Syndromes Associated
With Sensitization to HPA-1a
The two examples of anti-HPA-1a studied by
Shulman and his colleagues3 came from patients who
had received a blood transfusion and, 1 week later,
developed profound thrombocytopenia lasting about 3
weeks (Fig. 3). They coined the term “posttransfusion
purpura” (PTP) to define the combination of clinical
and serologic findings typical of this condition. By
1986, at least 75 well-documented cases of PTP, nearly
all associated with anti-HPA-1a antibodies, had been
described. Not long after their description of PTP,
Shulman et al.4 identified two more examples of anti-
HPA-1a in women who had given birth to infants with
severe neonatal alloimmune thrombocytopenia
(NATP), and provided the first description of that
condition involving maternal-fetal incompatibility for a
platelet-specific antigen. It is now recognized that
NATP occurs in about one of approximately every
1000 newborns, and that maternal-fetal incompatibility
of HPA-1a is responsible in the majority of cases.11
HPA-1a-Negative Platelets Were Used for the
First “Antigen-Compatible” Platelet
Transfusions
The recognition of NATP as a clinical entity raised
the issue of whether HPA-1a-negative (HPA-1b-positive)
platelets could be transfused successfully to infants
with thrombocytopenia caused by maternal anti-HPA-
1a. Because only 2 percent of the general population is
homozygous for HPA-1b and few blood banks were
capable of performing platelet typing in the 1960s,
platelets from HPA-1a-negative donors were not
generally available. However, Adner and colleagues12
showed that washed maternal platelets produced
satisfactory posttransfusion increments in an infant
with this condition. Because a mother’s platelets are
invariably compatible with her own antibody, this
approach has subsequently been used for treatment of
many infants born with NATP, regardless of the
specificity of the mother’s alloantibody.
Localization of HPA-1a to GPIIIa (the
Integrin β3 Subunit)
From studies done using techniques available in
1960, Shulman and colleagues3 concluded that HPA-1a
might reside on a relatively abundant platelet
membrane protein. An important clue to the actual
localization of the antigen came from the finding by
Kunicki and Aster13 that platelets from patients with
type I Glanzmann thrombasthenia, known to lack
glycoproteins IIb and IIIa, were invariably HPA-1a
negative. Kunicki and Aster14 then used immuno-
chemical methods to isolate GPIIIa, showed that it was
the carrier protein for HPA-1a, and speculated that the
Fig. 2. Early mutations in the GPIIIa gene in Homo sapiens gave rise to
polymorphisms responsible for creation of platelet alloantigenic
epitopes.
Fig. 3. PTP occurring 6 days after a blood transfusion in a 43-year-old
woman. Prednisone was without effect on the platelet count, but
spontaneous recovery occurred after about 3 weeks. A
complement-fixing antibody was detected on Day 11 and
declined to undetectable levels at about the time of platelet
recovery.*
*Reprinted with permission from Shulman et al.3
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antigen was held in a configuration suitable for
antibody recognition by one or more disulfide bonds.
Newman and colleagues15 soon thereafter localized the
HPA-1a epitope to a 17-kd tryptic fragment of the
GPIIIa and provided evidence that oligosaccharide
moieties were not required for immunogenicity.
Recognition that GPIIIa was one of the subunits of the
integrin αIIbβ316 enabled others to show that HPA-1a/b
alloantigens are not restricted to platelets, but can also
be expressed as part of the αvβ3 complex on
endothelial cells,17,18 macrophages, and fibroblasts.19
Genetic Basis for the HPA-1a/b
Polymorphism
Discovery of PCR in the mid-1980s made it possible
for the first time to identify nucleotide and amino acid
polymorphisms assumed to be responsible for the
creation of platelet alloantigens. Initially, it appeared
that this approach might not be applicable to “platelet
molecular biology” as platelets both lack a nucleus and
contain only vanishingly small amounts of mRNA. This
problem was circumvented by showing that mRNA
could be extracted from circulating platelets,
converted into cDNA, cloned, and then sequenced.20
Using this approach, Newman and colleagues21 then
sequenced cDNAs encoding GPIIIa from serologically
identified HPA-1a-positive and HPA-1a-negative
platelets and found a single nucleotide that accounted
for the generation of Leu33 (Pl
A1 = HPA-1a) and Pro33
(PlA2 = HPA-1b) allelic forms of GPIIIa. That the
Leu33Pro polymorphism was not only associated with
this alloantigen system but was directly responsible for
creating the alloantigenic epitope was later shown by
expressing the Leu33 and Pro33 forms of GPIIIa in
Chinese hamster ovary cells and demonstrating that
anti-HPA-1a human alloantisera bound only the Leu33
allelic isoform, whereas anti-HPA-1b sera reacted with
only the Pro33 form of the glycoprotein.
22 This
combined approach was subsequently used by us and
others to characterize nucleotide and amino acid
substitutions responsible for the creation of other
clinically important platelet-specific alloantigens,23–25
making possible routine DNA typing for most of the
platelet antigen systems,26,27 an application that is now
commonplace in transfusion medicine.
PlA1 at Last! Structural Characterization of a
Platelet-Specific Alloantigen
The discovery that the HPA-1a and -1b alloantigen
system was controlled by a polymorphism at amino
acid 33 of GPIIIa, together with a complex biochemical
analysis of disulfide bond assignments within GPIIIa,28
facilitated generation of several models of the HPA-1a
and HPA-1b epitopes.One such early model is shown in
Figure 4, which depicts a circular peptide loop held
together by cysteine residues 26 and 38 that was
predicted to form the alloantigen. Frustratingly,
however, when cyclic peptides expected to contain
HPA-1a/b were synthesized, they were found to be
incapable of reacting with HPA-1a- and HPA-1b-specific
antibodies.29 An explanation for this apparent anomaly
was finally provided by Springer and colleagues,30 who
determined the actual crystal structure of the N-
terminal plextrin-semaphorin-integrin (PSI) homology
domain of GPIIIa—the domain that encompasses
polymorphic residue 33. In addition to providing the
correct disulfide bond assignments, this landmark study
provided the coordinates of the PSI domain at the N-
terminus of β3 integrin and made it possible to
visualize for the first time the region of GPIIIa that
controls formation of the HPA-1a and HPA-1b epitopes
(Fig. 5)—some 45 years after the initial description of
this platelet alloantigen system! More work remains,
however, because the actual surface in GPIIIa
recognized by HPA-1a-specific antibodies appears to be
complex, as Valentin and coworkers31 found that
Fig. 4. Schematic diagrams from the early 1990s of the hypothetical
structure of the GPIIb-IIIa complex (upper left). The amino
terminus of GPIIIa, including a small disulfide-bonded loop that
was thought at that time to be formed by amino acids 26 and 38
and to encompass polymorphic amino acid residue 33 (PlA1/PlA2
controlling region) is shown in the upper right (encircled).
Bottom: an early molecular model of the Leu33 and Pro33 forms of
the AA 26–38 loop thought to encompass the PlA1 and PlA2
alloantigenic epitopes. Modeling was performed by Jack Gorski,
Blood Research Institute, BloodCenter of Wisconsin, using SYBIL
molecular modeling software running on a Silicon Graphics
Workstation.
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certain mutant forms of GPIIIa are recognized by some,
but not all, HPA-1a-specific antibodies, and devised the
terms “type 1” and “type 2” to describe those that
require a cysteine residue at amino acid residue 435
and those that do not, respectively. It seems likely that
type 1 antibodies recognize a peptide sequence
containing Leu33 plus a noncontiguous peptide
sequence near Cys435.
The Immune Response to HPA-1a is Unique
As blood banks and other laboratories acquired the
ability to detect HPA-1a-specific antibodies, it soon
became apparent that not all HPA-1a-negative
individuals challenged with HPA-1a-positive platelets
became sensitized to this antigen. In a series of studies
begun in the 1980s,32,33 it was found that HPA-1a is
unique among blood group antigens in inducing an
immune response that is almost invariably linked to the
class II HLA marker DRB3*010134 or DQB1*02.35 In the
case of NATP, the relative risk for a fetus that is HPA-1a
incompatible with its mother is approximately 141 if
the woman is positive for DRB3*0101, roughly the
same as the risk of developing ankylosing spondylitis in
HLA-B27-positive individuals.36 The allele HPA-1b
induces antibodies much less often than HPA-1a, and
the response to this marker is not HLA-linked.37
A potential explanation for the remarkable
association between the immune response to HPA-1a
and HLA was provided by Gorski and associates.36,38 In
one series of studies, they showed that T cells from two
women who had produced anti-HPA-1a antibodies are
specifically stimulated by a cyclic peptide containing
the polymorphism that controls HPA-1a expression
(residues 27–37 of the HPA-1a allele of GPIIIa, β3
integrin) but not by the same set of peptides from the
HPA-1b allele (Leu to Pro at amino acid residue 33).36
Interestingly, a common complementarity determining
region motif was identified in responding T cells from
two different women, despite use of genes from
different V beta families to encode the peptide
recognition domain. These findings showed that the
response to HPA-1a is unusual in that the same peptide
is recognized by both B-cell and T-cell receptors. The
same group then found that a peptide containing Leu33
bound tightly to recombinant DRB3*1010 whereas the
one containing Pro33 was nonreactive, thus providing a
molecular explanation for the unidirectional nature of
the immune response to HPA-1 antigens.38
The HPA-1a/b Alloantigen System in
Hemostasis
A new and still evolving chapter in the HPA-1a/b
story began with observations by Weiss and
coworkers39 that persons admitted to an intensive care
unit with myocardial infarction were more likely to be
positive for HPA-1b than individuals from the general
population. This association appeared to be particu-
larly significant in younger individuals. This report set
off a series of epidemiological and biochemical studies
that are remarkable for lack of consensus in nearly 100
published reports. For example, one study found that
fibrinogen binds more readily to GPIIb/IIIa on
activated HPA-1b-positive platelets than on HPA-1b-
negative platelets,40 but no difference was found by
two other groups.41,42 Various reports suggested that
HPA-1b-positive individuals are at higher risk for
thrombosis or premature atherosclerosis42,43 and even
renal transplant rejection.44 However, a retrospective
analysis of DNA samples from almost 15,000
individuals found no association between HPA-1b and
thrombosis, atherosclerosis, or stroke.45 HPA-1b-
positive platelets were found to be hypersensitive to
the agonist ADP in one study46 and resistant to
activation by thrombin receptor activating peptide in
another.47 Recent work has provided a certain amount
of objective biochemical evidence that HPA-1b-positive
Fig. 5. PlA1 at last! The amino terminal PSI domain of GPIIIa, based on
the actual crystal structure of the molecule, is shown in four
different rotated views. Amino acid 33 is portrayed as a ball and
stick structure at the base of a disulfide-bonded loop formed by
residues 16 and 38. The structure is complicated by the presence
of two additional cysteine residues within this loop—one at
amino acid 23, and the other at residue 26—making mimicking
the epitope for potential therapeutic purposes an extremely
challenging task. Amino acid strands connecting the PSI domain
to the hybrid domain of GPIIIa are shown at the top of each
structure.
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platelets may be “hyperfunctional” in several
respects.48,49 Perhaps further work along these lines
will provide an explanation for apparently discordant
observations made at the clinical level.
Conclusion
Since the alloantigen system now designated HPA-
1a/b was discovered about 1960, serologic,
biochemical, epidemiologic, and molecular biological
studies of this diallelic alloantigen system have
contributed importantly to our understanding of
alloimmune thrombocytopenia, the cellular and
humoral basis of the alloimmune response, the
structural basis of alloantigenicity, and platelet
pathophysiology. As more is yet to be learned, it is to
be hoped that further examination of this remarkable
alloantigen system will be similarly rewarding.
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